Cynata Therapeutics Limited

Cynata Therapeutics Limited is focused on clinical research in high-risk acute graft-versus-host disease, with particular attention to immune-mediated complications that arise after stem cell transplantation. Its current trial activity centres on adult patients with severe acute GvHD requiring treatment support.

• High-risk acute graft-versus-host disease
• Post-transplant immune complications
• Allogeneic stem cell transplantation

The sponsor’s research activity is directed toward clinical settings where immune dysregulation and tissue injury contribute to significant morbidity in transplant recipients.